Navigation Links
EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patient
Date:10/16/2009

WELLESLEY Hills, Mass., Oct. 16 /PRNewswire/ -- The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept(®)(10 mg). Based on the marked progress during the original two week study, the patient's daughter sought continued compassionate use of PRX-03140 for her mother and a protocol was submitted to the FDA and approved. The progress seen in the first 2-week study has continued during the past two years (19 months of dosing) and four FDA approved 6-month open label extensions. The latest open label extension will be administered under a new Physician-Sponsored IND under the supervision of Dr. Lucy Hornstein(1). "When I was approached by the patient's daughter to continue the compassionate use therapy of PRX-03140 for her mother, I was compelled by the progress her mother had experienced and the overall apparent safety of the drug," notes Dr. Hornstein.

On July 20, 2009, EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481.

The
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
2. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
3. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
4. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
5. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
6. China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
7. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
8. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
9. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
10. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
11. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- ExeGi Pharma, a company focused on developing and ... it has been granted a product license by the ... to sell Visbiome™ in Canada . ... Claudio De Simone , MD, PhD and has been ... recently signed an exclusive agreement with ExeGi Pharma to ...
(Date:7/1/2015)... 2015 According to a new ... Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), ... Global Forecast to 2020", published by MarketsandMarkets, the Transfection ... $957.9 Million by 2020 with a CAGR of 7.2% ... market T ables and 33 F ...
(Date:7/1/2015)... Mass. , July 1, 2015 Boston Scientific ... discussing financial results and business highlights for the second quarter ... 8 a.m. ET. The call will be hosted ... and Dan Brennan , executive vice president and chief ... call will be available via the Boston Scientific website. Webcast ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... WIRE)--May 21, 2007 - Results from a new,study, ... (DDW),conference, showed that more than 99 percent of ... were treated,successfully with PEGASYS(R) (peginterferon alfa-2a) had no,detectable ... the use of,the word "cured" to describe these ...
... Shows Promising Treatment for People Suffering,from Barrett's ... WILMINGTON, MASSACHUSETTS--(CCNMatthews - May 17, 2007) - ... U.S. Food,and Drug Administration (FDA) has granted ... Photodynamic Therapy (PDT),for the treatment of esophageal ...
Cached Medicine Technology:Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 2Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 5Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 6DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 2DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 3DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 4
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... Louisville, KY (PRWEB) , ... July 01, 2015 ... ... Health Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying ... The paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . ...
(Date:7/1/2015)... Columbus, OH (PRWEB) , ... July 01, 2015 , ... ... pleased to announce Dr. Leslie King has been named Dean of the ... role as Dean, Dr. King will promote and support the vision and mission of ...
(Date:7/1/2015)... Luis Obispo, CA (PRWEB) , ... July 01, ... ... non-surgical bunion treatment, announces their big summer sale. Customers purchasing two or ... with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned toes ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... A team of French surgeons took off on a specially ... attempt the first-ever operation // carried out in weightless ... ,The Airbus A300 is equipped with a special surgical module, ... future surgery carried out in the gravity-free conditions of outer ...
... of patented drugs will play host to a new entrant ... recent communique // by the Director of patent policy in ... arm for the multitude of generic drug manufacturers, who can ... to developing nations. ,Biolyse Pharma Corp., ...
... in the U.S. uncovered the secrets of the deadly Spanish flu ... across the world.// ,The pandemic took lives of ... severity of the virus was not understood then. ,Dr John Kash, ... a research by infecting mice with a reconstructed form of the ...
... Thiruvananthapuram: The Health Department has announced that it ... both prevention as well as // control measures, ... districts in Kerala, Thiruvananthapuram, Alappuzha, Ernakulum and Kozhikode ... of a slackened response by the Health watch ...
... a division that deals with the reconstruction of the ... the occurrence of birth defects like cleft palate. Since ... required. This will not only ensure a smooth operation, ... their face will look like in future., ,In ...
... cornea cells that may also explain how it evades the ... University of Illinois at Chicago College of Medicine. ... Journal of Cell Biology. ,Both strains of the ... on the mouth, and HSV-2, genital herpes -- can infect ...
Cached Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:Mathematics And Beauty? You Bet! 2Health News:Herpes Infects Cornea, Evades Immune Cells 2
PDA application contains 15,000+ ICD-9-CM Diagnosis codes....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Athouritative, on the spot answers for acute care and consultations....
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
Medicine Products: